CCL5 and non-small cell lung carcinoma: Our results showed that MIP-1β was obviously elevated in NSCLC patients after radiotherapy, in comparison with these patients before radiotherapy, and there were more expressions of RANTES and I-309 of NSCLC patients in the post-RT group than in the HC group.